Eastern Bank Buys Shares of 1,500 CRISPR Therapeutics AG (NASDAQ:CRSP)

Eastern Bank purchased a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) during the 3rd quarter, HoldingsChannel reports. The fund purchased 1,500 shares of the company’s stock, valued at approximately $70,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Riggs Asset Managment Co. Inc. grew its stake in shares of CRISPR Therapeutics by 66.7% during the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after buying an additional 200 shares during the last quarter. Global Trust Asset Management LLC lifted its holdings in shares of CRISPR Therapeutics by 150.0% during the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock valued at $27,000 after purchasing an additional 300 shares during the last quarter. Larson Financial Group LLC lifted its holdings in shares of CRISPR Therapeutics by 95.5% during the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after purchasing an additional 276 shares during the last quarter. GPS Wealth Strategies Group LLC lifted its holdings in shares of CRISPR Therapeutics by 99.7% during the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock valued at $33,000 after purchasing an additional 307 shares during the last quarter. Finally, Itau Unibanco Holding S.A. purchased a new position in shares of CRISPR Therapeutics during the second quarter valued at approximately $35,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Performance

CRSP stock opened at $47.36 on Friday. The firm has a market cap of $4.02 billion, a PE ratio of -17.41 and a beta of 1.68. The firm’s fifty day moving average is $47.18 and its 200 day moving average is $52.84. CRISPR Therapeutics AG has a one year low of $38.16 and a one year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $12.31 million. During the same quarter last year, the business posted ($0.98) EPS. The firm’s revenue for the quarter was down 99.3% on a year-over-year basis. Research analysts predict that CRISPR Therapeutics AG will post -5.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CRSP has been the subject of several analyst reports. Truist Financial reduced their price target on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Royal Bank of Canada cut their price objective on shares of CRISPR Therapeutics from $60.00 to $53.00 and set a “sector perform” rating for the company in a research report on Friday, October 4th. Stifel Nicolaus lowered their target price on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Barclays lowered their target price on shares of CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 6th. Finally, Chardan Capital lowered their target price on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $75.19.

Insider Activity

In other news, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the sale, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.